Guardant Health (FRA:5GH) FFO


FRA:5GH Guardant Health Inc FRA:5GH
67 GF Score
Price €124.64
GF Value €50.44
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Guardant Health FFO?

FFO (Funds from operations) only applies to REITs.

FRA:5GH
67GF Score
Guardant Health Inc FRA:5GH
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Guardant Health (FRA:5GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €124.64 is trading 147.1% above its estimated GF Value™ of €50.44. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for FRA:5GH:

  • FFO:
  • GF Value™: €50.44 vs. price of €124.64 (147.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score

Get the complete analysis for FRA:5GH

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€124.64
Price
€50.44
GF Value